Compare iShares International Treasury Bond ETF (IGOV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.31B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 5.6× iShares International Treasury Bond ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IGOV | SYRE | |
|---|---|---|
Market Cap | $1.31B | $7.35B |
Volume | 69,817 | 1,624,631 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $108.92 |
52-Week Low | $39.58 | $22.18 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.79, up 0.53% with mixed technical signals showing bearish moving averages but bullish oscillators. The stock faces resistance at $40-$42 while finding support near $39. Financial ratios remain unavailable, requiring deeper fundamental analysis to assess valuation and profitability metrics.
The stock's outlook remains uncertain with technical indicators conflicting and limited fundamental data available. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETF opportunities mentioned in recent news could signal defensive positioning. Investors need updated financial disclosures to properly evaluate investment merit.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
